Benzinga | Jun 11, 2021 08:26AM EDT

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $281

Cantor Fitzgerald analyst Alethia Young maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $285 to $281.